{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T11:57:47Z","timestamp":1793447867326,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>We recently reported that short-term treatment with liraglutide (20.0\u2009\u00b1\u20096.4\u2009days) reduced body weight and improved some scales of eating behavior in Japanese type 2 diabetes inpatients. However, it remained uncertain whether such liraglutide-induced improvement is maintained after discharge from the hospital. The aim of the present study was to determine the long-term effects of liraglutide on body weight, glycemic control, and eating behavior in Japanese obese type 2 diabetics.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Patients with obesity (body mass index (BMI) &gt;25\u2009kg\/m<jats:sup>2<\/jats:sup>) and type 2 diabetes were hospitalized at Osaka University Hospital between November 2010 and December 2011. BMI and glycated hemoglobin (HbA1c) were examined on admission, at discharge and at 1, 3, and 6\u2009months after discharge. For the liraglutide group (BMI; 31.3\u2009\u00b1\u20095.3\u2009kg\/m<jats:sup>2<\/jats:sup>, n\u2009=\u200929), patients were introduced to liraglutide after correction of hyperglycemic by insulin or oral glucose-lowering drugs and maintained on liraglutide after discharge. Eating behavior was assessed in patients treated with liraglutide using The Guideline For Obesity questionnaire issued by the Japan Society for the Study of Obesity, at admission, discharge, 3 and 6\u2009months after discharge. For the insulin group (BMI; 29.1\u2009\u00b1\u20093.0\u2009kg\/m<jats:sup>2<\/jats:sup>, n\u2009=\u200928), each patient was treated with insulin during hospitalization and glycemic control maintained by insulin after discharge.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Liraglutide induced significant and persistent weight loss from admission up to 6\u2009months after discharge, while no change in body weight after discharge was noted in the insulin group. Liraglutide produced significant improvements in all major scores of eating behavior questionnaire items and such effect was maintained at 6\u2009months after discharge. Weight loss correlated significantly with the decrease in scores for recognition of weight and constitution, sense of hunger, and eating style.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Liraglutide produced meaningful long-term weight loss and significantly improved eating behavior in obese Japanese patients with type 2 diabetes.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1475-2840-11-107","type":"journal-article","created":{"date-parts":[[2012,9,15]],"date-time":"2012-09-15T01:47:26Z","timestamp":1347673646000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes"],"prefix":"10.1186","volume":"11","author":[{"given":"Yuya","family":"Fujishima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norikazu","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Kashine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Nishizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumu","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Kozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuyuki","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Okita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihisa","family":"Imagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Funahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iichiro","family":"Shimomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,9,14]]},"reference":[{"key":"515_CR1","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJMoa1010679","volume":"364","author":"W Zheng","year":"2011","unstructured":"Zheng W, McLerran DF, Rolland B, Zhang X, Inoue M, Matsuo K, He J, Gupta PC, Ramadas K, Tsugane S, Irie F, Tamakoshi A, Gao YT, Wang R, Shu XO, Tsuji I, Kuriyama S, Tanaka H, Satoh H, Chen CJ, Yuan JM, Yoo KY, Ahsan H, Pan WH, Gu D, Pednekar MS, Sauvaget C, Sasazuki S, Sairenchi T, Yang G, Xiang YB, Nagai M, Suzuki T, Nishino Y, You SL, Koh WP, Park SK, Chen Y, Shen CY, Thornquist M, Feng Z, Kang D, Boffetta P, Potter JD: Association between body-mass index and risk of death in more than 1 million Asians. N Engl J Med. 2011, 364: 719-729. 10.1056\/NEJMoa1010679.","journal-title":"N Engl J Med"},{"key":"515_CR2","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1016\/j.amjmed.2010.11.004","volume":"124","author":"R Chilton","year":"2011","unstructured":"Chilton R, Wyatt J, Nandish S, Oliveros R, Lujan M: Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagon like peptide-1-based therapies. Am J Med. 2011, 124: S35-S53. 10.1016\/j.amjmed.2010.11.004.","journal-title":"Am J Med"},{"key":"515_CR3","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","unstructured":"UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998, 352: 837-853.","journal-title":"Lancet"},{"key":"515_CR4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/j.1463-1326.2009.01075.x","volume":"Suppl 3","author":"L Blonde","year":"2009","unstructured":"Blonde L, Russell-Jones D: The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1\u20135 studies. Diabetes Obes Metab. 2009, Suppl 3: 26-34.","journal-title":"Diabetes Obes Metab"},{"key":"515_CR5","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.diabres.2008.03.018","volume":"81","author":"Y Seino","year":"2008","unstructured":"Seino Y, Rasmussen MF, Zdravkovic M, Kaku K: Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2008, 81: 161-168. 10.1016\/j.diabres.2008.03.018.","journal-title":"Diabetes Res Clin Pract"},{"key":"515_CR6","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1185\/03007991003672551","volume":"26","author":"Y Seino","year":"2010","unstructured":"Seino Y, Rasmussen MF, Nishida T, Kaku K: Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes. Curr Med Res Opin. 2010, 26: 1013-1022. 10.1185\/03007991003672551.","journal-title":"Curr Med Res Opin"},{"key":"515_CR7","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/j.1463-1326.2009.01194.x","volume":"12","author":"K Kaku","year":"2010","unstructured":"Kaku K, Rasmussen MF, Clauson P, Seino Y: Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes. Diabetes Obes Metab. 2010, 12: 341-347. 10.1111\/j.1463-1326.2009.01194.x.","journal-title":"Diabetes Obes Metab"},{"key":"515_CR8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/1475-2840-10-109","volume":"10","author":"K Inoue","year":"2011","unstructured":"Inoue K, Maeda N, Kashine S, Fujishima Y, Kozawa J, Hiuge-Shimizu A, Okita K, Imagawa A, Funahashi T, Shimomura I: Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes. Cardiovasc Diabetol. 2011, 10: 109-10.1186\/1475-2840-10-109.","journal-title":"Cardiovasc Diabetol"},{"key":"515_CR9","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1007\/s00125-009-1472-y","volume":"52","author":"D Russell-Jones","year":"2009","unstructured":"Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, Zdravkovic M, Ravn GM, Sim\u00f3 R: Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met\u2009+\u2009SU Study Group. Diabetologia. 2009, 52: 2046-2055. 10.1007\/s00125-009-1472-y.","journal-title":"Diabetologia"},{"key":"515_CR10","first-page":"165","volume":"5","author":"H Berlie","year":"2012","unstructured":"Berlie H, Hurren KM, Pinelli NR: Glucagon-like peptide-1 receptor agonists as add-on therapy to basal insulin in patients with type 2 diabetes: a systematic review. Diabetes Metab Syndr Obes. 2012, 5: 165-174.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"515_CR11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.2337\/db06-0565","volume":"56","author":"K Raun","year":"2007","unstructured":"Raun K, von Voss P, Gotfredsen CF, Golozoubova V, Rolin B, Knudsen LB: Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes. 2007, 56: 8-15. 10.2337\/db06-0565.","journal-title":"Diabetes"},{"key":"515_CR12","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1038\/oby.2007.204","volume":"15","author":"K Raun","year":"2007","unstructured":"Raun K, von Voss P, Knudsen LB: Liraglutide, a once-daily human glucagon-like peptide-1 analog, minimizes food intake in severely obese minipigs. Obesity. 2007, 15: 1710-1716. 10.1038\/oby.2007.204.","journal-title":"Obesity"},{"key":"515_CR13","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1210\/jc.2008-1296","volume":"94","author":"R Abu-Hamdah","year":"2009","unstructured":"Abu-Hamdah R, Rabiee A, Meneilly GS, Shannon RP, Andersen DK, Elahi D: Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab. 2009, 94: 1843-1852. 10.1210\/jc.2008-1296.","journal-title":"J Clin Endocrinol Metab"},{"key":"515_CR14","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.diabres.2012.02.016","volume":"97","author":"M Horowitz","year":"2012","unstructured":"Horowitz M, Flint A, Jones KL, Hindsberger C, Rasmussen MF, Kapitza C, Doran S, Jax T, Zdravkovic M, Chapman IM: Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. Diabetes Res Clin Pract. 2012, 97: 258-266. 10.1016\/j.diabres.2012.02.016.","journal-title":"Diabetes Res Clin Pract"},{"key":"515_CR15","first-page":"672658","volume":"2012","author":"M Monami","year":"2012","unstructured":"Monami M, Dicembrini I, Marchionni N, Rotella CM, Mannucci E: Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis. Exp Diabetes Res. 2012, 2012: 672658.","journal-title":"Exp Diabetes Res"},{"key":"515_CR16","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","volume":"374","author":"A Astrup","year":"2009","unstructured":"Astrup A, R\u00f6ssner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, Madsen J, Rasmussen MF, Lean ME: NN8022-1807 Study Group: Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009, 374: 1606-1616. 10.1016\/S0140-6736(09)61375-1.","journal-title":"Lancet"},{"key":"515_CR17","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1007\/s00125-008-0943-x","volume":"51","author":"PV H\u00f8jberg","year":"2008","unstructured":"H\u00f8jberg PV, Zander M, Vilsb\u00f8ll T, Knop FK, Krarup T, V\u00f8lund A, Holst JJ, Madsbad S: Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes. Diabetologia. 2008, 51: 632-640. 10.1007\/s00125-008-0943-x.","journal-title":"Diabetologia"},{"key":"515_CR18","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s00125-008-1195-5","volume":"52","author":"PV H\u00f8jberg","year":"2009","unstructured":"H\u00f8jberg PV, Vilsb\u00f8ll T, Rab\u00f8l R, Knop FK, Bache M, Krarup T, Holst JJ, Madsbad S: Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia. 2009, 52: 199-207. 10.1007\/s00125-008-1195-5.","journal-title":"Diabetologia"},{"key":"515_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1475-2840-9-17","volume":"9","author":"M Yamaoka-Tojo","year":"2010","unstructured":"Yamaoka-Tojo M, Tojo T, Takahira N, Matsunaga A, Aoyama N, Masuda T, Izumi T: Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease. Cardiovasc Diabetol. 2010, 9: 17-10.1186\/1475-2840-9-17.","journal-title":"Cardiovasc Diabetol"},{"key":"515_CR20","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.bbrc.2010.12.021","volume":"404","author":"S Kawashima","year":"2011","unstructured":"Kawashima S, Matsuoka TA, Kaneto H, Tochino Y, Kato K, Yamamoto K, Yamamoto T, Matsuhisa M, Shimomura I: Effect of alogliptin, pioglitazone and glargine on pancreatic \u03b2-cells in diabetic db\/db mice. Biochem Biophys Res Commun. 2011, 404: 534-540. 10.1016\/j.bbrc.2010.12.021.","journal-title":"Biochem Biophys Res Commun"},{"key":"515_CR21","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.2337\/dc10-2415","volume":"34","author":"RR Wing","year":"2011","unstructured":"Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, Hill JO, Brancati FL, Peters A, Wagenknecht L: Look AHEAD Research Group: Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011, 34: 1481-1486. 10.2337\/dc10-2415.","journal-title":"Diabetes Care"},{"key":"515_CR22","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1185\/030079907X253870","volume":"24","author":"DC Klonoff","year":"2008","unstructured":"Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME, Maggs DG: Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3\u2009years. Curr Med Res Opin. 2008, 24: 275-286.","journal-title":"Curr Med Res Opin"},{"key":"515_CR23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/1475-2840-10-61","volume":"10","author":"S Ansar","year":"2011","unstructured":"Ansar S, Koska J, Reaven PD: Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins. Cardiovasc Diabetol. 2011, 10: 61-10.1186\/1475-2840-10-61.","journal-title":"Cardiovasc Diabetol"},{"key":"515_CR24","doi-asserted-by":"publisher","first-page":"E1209","DOI":"10.1152\/ajpendo.00237.2004","volume":"287","author":"T Nystr\u00f6m","year":"2004","unstructured":"Nystr\u00f6m T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahr\u00e9n B, Sj\u00f6holm A: Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab. 2004, 287: E1209-E1215. 10.1152\/ajpendo.00237.2004.","journal-title":"Am J Physiol Endocrinol Metab"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1475-2840-11-107.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T19:45:16Z","timestamp":1630525516000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/1475-2840-11-107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,14]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["515"],"URL":"https:\/\/doi.org\/10.1186\/1475-2840-11-107","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,14]]},"assertion":[{"value":"13 July 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"107"}}